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Abstract 
Background: Despite the availability of effective preventive measures, including intermittent preventive treatment 
for malaria during pregnancy (IPTp), malaria continues to cause substantial disease burden among pregnant women 
in malaria-endemic areas. IPTp coverage remains low, despite high antenatal care (ANC) attendance. To highlight 
areas of potential improvement, trends in IPTp coverage were assessed over time, missed opportunities to deliver IPTp 
at ANC were quantified, and delivery of IPTp was compared to that of tetanus toxoid (TT).
Methods: Data from 58 Demographic and Health Surveys conducted between 2003 and 2013 in 31 sub-Saharan 
African countries, with relevant questions on IPTp, ANC and TT were used to assess ANC attendance, and IPTp and TT 
delivery. A missed opportunity for IPTp delivery is an ANC visit at which IPTp could have been delivered according to 
policy but was not.
Results: The proportion of pregnant women who received ≥2 doses of IPTp increased in surveyed countries from 
nearly zero before to a median of 29.6 % (IQR 20.1–42.5 %) seven or more years after IPTp policy adoption. ANC 
attendance was high (median 76.6 % reported ≥3 visits); however, even seven or more years post policy adoption, a 
median of 72.9 % (IQR 58.4–79.5 %) ANC visits were missed opportunities to deliver IPTp. Among primigravid women, 
a median of 61.5 % (IQR 50.9–72.9 %) received two doses of TT; delivery of recommended TT exceeded IPTp in all but 
one surveyed country.
Conclusions: IPTp coverage measured by household surveys is unsatisfactorily low, even many years after policy 
adoption. The many missed opportunities to deliver IPTp suggest that deficiencies in delivery at ANC are a signifi-
cant contributing factor to the low coverage levels. High levels of TT delivery indicate capacity to deliver preventive 
measures at ANC. Further research is required to determine the factors driving the discrepancies between IPTp and TT 
coverage, and how these may be addressed to improve IPTp coverage.
© 2015 Andrews et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite international calls for malaria eradication [1] and 
the availability of many low-cost interventions to prevent 
malaria morbidity and mortality, the disease continues 
to be responsible for a substantial public health burden 
in affected populations, causing one death every min-
ute [2]. In 2013, there were an estimated 198 million 
(uncertainty range 124–283 million) malaria cases, and 
584,000 (uncertainty range 367–755,000) malaria deaths 
globally, the majority of which occurred in sub-Saharan 
Africa, primarily among children under 5  years old [3]. 
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In addition to children under five, malaria disproportion-
ately affects pregnant women, and an estimated 125 mil-
lion pregnancies occur annually in malaria-endemic areas 
[4]. Malaria in pregnancy is associated with increased 
risk of maternal anaemia, low birth weight, and neonatal 
mortality [5].
Along with insecticide-treated bed nets (ITNs) and 
effective treatment and diagnosis of clinical malaria, 
intermittent preventive treatment for malaria during 
pregnancy (IPTp) with sulfadoxine–pyrimethamine (SP) 
is one of the strategies recommended to prevent the 
adverse consequences of malaria in pregnancy [6]. IPTp 
consists of administering a single-dose, oral anti-malarial 
to all pregnant women, irrespective of whether they have 
malaria. Currently, SP is the only drug recommended 
for IPTp. IPTp-SP reduces maternal malaria and anae-
mia and improves infant birth weight [7]. The effect on 
birth weight is maintained even in the context of wide-
spread ITN use and in areas with widespread resistance 
to SP [5]. In an analysis of national survey data, IPTp-
SP reduced the odds of low birth weight (adjusted odds 
ratio 0.75 [95 % confidence interval CI 0.71–0.80]) com-
pared to not using either IPTp-SP or ITNs; the protective 
effect remained even for women who lived in households 
with an ITN [8]. It is a highly cost-effective intervention 
for preventing maternal malaria and reducing neonatal 
mortality [9]. Since 2004, the World Health Organiza-
tion (WHO) has recommended that women receive a 
minimum of two doses of IPTp-SP during pregnancy. In 
2012 the policy was updated to recommend that IPTp-SP 
be administered at every scheduled antenatal care (ANC) 
visit starting in the second trimester, provided that doses 
are at least 1  month apart [6]. As WHO recommends 
three ANC visits during the second and third trimesters 
of pregnancy [10, 11], there should be ample opportu-
nities for administration to allow a high proportion of 
women to receive three doses. Since 2011, the goal set by 
Roll Back Malaria has been that by 2015, 100 % of preg-
nant women at risk of malaria should receive at least two 
doses of IPTp-SP, in settings where IPTp is appropriate 
[12]. Despite relatively high ANC attendance, and the 
modest system requirements needed to deliver a single-
dose, oral prophylactic in a clinic setting, coverage of 
IPTp-SP has been low in sub-Saharan Africa [13].
Coverage of health interventions delivered at a health 
facility depends on attendance of targeted groups and 
delivery of the intervention at a facility. For IPTp-SP, 
pregnant women may present too late or too few times 
for ANC to receive the recommended number of doses; 
however, some studies suggest that healthcare workers 
do not administer SP, either due to confusion over the 
guidance or because they are too busy or lack supplies 
[14]. Quantifying the missed opportunities to deliver an 
intervention allows for assessment of the effectiveness of 
the healthcare system to deliver that intervention, isolat-
ing the effects of shortcomings in provision of interven-
tions at point-of-care from patients’ failure to seek care. 
Following the most recent WHO guidelines for adminis-
tering IPTp-SP [10], for women not taking cotrimoxazole 
prophylaxis, each scheduled ANC visit in the second or 
third trimester is an opportunity to deliver IPTp-SP, and 
any of these visits where IPTp-SP is not administered 
could be considered a ‘missed opportunity’.
Many interventions are delivered to women through 
the ANC platform. Tetanus toxoid immunization (TT) 
has been routinely administered to pregnant women 
since the 1980s to prevent neonatal tetanus, an acute dis-
ease which generally presents in the first 2 weeks of life 
and carries a 10–100  % case fatality rate, depending on 
the level of care received [15]. Two doses of tetanus tox-
oid (TT2) delivered at least 4 weeks apart (at the first and 
second ANC visits) are recommended for all primigravid 
women. In contrast to IPTp-SP, TT2 routinely achieves 
high coverage levels [16], despite the fact that it is an 
injection and requires refrigeration [17]. To understand 
how successfully health systems are delivering IPTp-SP, 
all available surveys from the Demographic and Health 
Surveys (DHS) programme [18] from 2003 to 2013, span-
ning the implementation of IPTp-SP programmes, were 
used to explore missed opportunities for IPTp-SP admin-
istration and compare IPTp-SP coverage to that of TT.
Methods
Data
Seventy household survey datasets from the DHS pro-
gramme website [18] conducted between 2000 and 2013, 
with relevant survey questions, were identified; these 
included standard DHS, AIDS indicator surveys (AIS), 
and malaria indicator surveys (MIS) from 32 coun-
tries in sub-Saharan Africa (Fig.  1; see also Additional 
file 1: Table S1 for a complete table of included surveys 
and respective IPTp and TT coverage). Twelve surveys 
where information on precise numbers of IPTp-SP doses 
was missing were excluded, leaving 58 surveys from 31 
countries (2003–2013) for analysis. All of these surveys 
included a module with questions on pregnancies result-
ing in live births in the past 5 years and relied on women’s 
ability to recall their pregnancy experiences over this 
time period [18]. To ensure that estimates were calcu-
lated using independent observations from recent births, 
analyses were performed using, for each woman sur-
veyed, the most recent pregnancy resulting in a live birth 
within the 2 years prior to the survey date. Data on ANC 
attendance and TT administration were available in 44 
of the 58 surveys. STATA SE statistical software package 
version 13.1 (StataCorp, College Station, TX, USA) was 
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used for all analyses, and all mean and CI estimates were 
weighted to account for survey design.
Data analysis
Among women whose most recent pregnancy resulted in 
a live birth in the past 2 years, the proportion receiving 
two or more doses and the proportion receiving three or 
more doses of IPTp-SP were calculated for each survey. 
As nearly all surveys were conducted before the updated 
WHO policy in 2012 emphasizing dosing of IPTp-SP at 
each ANC visit, the proportion receiving two or more 
doses of IPTp-SP was used as the primary comparison 
in this analysis. In addition, to assess implementation 
of IPTp-SP over time since policy adoption, the median 
coverage across countries was assessed for surveys con-
ducted during three periods in reference to IPTp-SP 
policy adoption: (1) pre-adoption, which included any 
surveys conducted from 2003 until the year after policy 
was adopted in a given country; (2) early post-adoption 
defined as the 5  year period starting 2  years after the 
policy was adopted; and (3) late post-adoption, which 
included any surveys conducted seven or more years 
after a country formally adopted an IPTp-SP policy (see 
Additional file 1: Table S1 for a list of surveys and their 
policy periods). Year of IPTp policy adoption was taken 
from the World Malaria Report and proposals that were 
submitted to the Global Fund to Fight AIDS, Tubercu-
losis and Malaria [19]. Because IPTp-SP coverage cal-
culated from a given survey was actually based on data 
from the 2 years preceding the survey, and a survey was 
not available in every year for each country, present-
ing results based on these groupings (rather than calen-
dar year) allowed for more meaningful interpretation of 
changes in coverage. In addition, this grouping allowed 
Fig. 1 Map of Africa showing countries included in the analysis. A total of 58 surveys conducted by Measure DHS between 2003 and 2013 were 
included from the 31 shaded sub-Saharan African countries [18]
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for lag time between adoption and implementation of a 
new policy. For those countries where two or more sur-
veys were available, with at least one following the adop-
tion of an IPTp-SP policy, the median 5 year annualized 
difference in IPTp-SP coverage was calculated between 
the surveys by taking the absolute difference in percent-
age points of coverage between one survey and the next 
within the same country and dividing this difference by 
the number of years that elapsed between the surveys. 
Since the annual change was quite small, it was mul-
tiplied by five to provide a more salient value, which is 
interpreted as the change in coverage over 5 years. This 
metric provides an estimate of the absolute change in 
coverage over time.
Among women whose most recent pregnancy resulted 
in a live birth in the past 2 years, the percentage of missed 
opportunities to deliver IPTp-SP was defined as:
Given the limitations of available data, some assumptions 
were required for this calculation. As only the timing of 
the first visit, but not of subsequent visits, was collected 
in these surveys, it was assumed that no more than one 
first trimester visit occurred (WHO recommends only 
one visit in the first trimester [11]). In other words, the 
number of ANC visits occurring in the second and third 
trimester was calculated by subtracting one visit from the 
total number of ANC visits for any woman who reported 
that her first visit occurred in the first trimester. All ANC 
visits were assumed to take place at intervals of at least 
1 month and all IPTp-SP doses reported were assumed to 
have occurred during ANC visits. HIV-infected women 
taking cotrimoxazole prophylaxis for the prevention 
of opportunistic infections are not eligible for IPTp-SP 
because of the increased risk of adverse drug reactions 
when these medications are taken concomitantly [20], 
and therefore their ANC visits should not be included in 
the calculation of missed opportunities. However, in the 
household surveys analysed, no data were collected on 
cotrimoxazole administration, therefore it was not pos-
sible to account for this.
To understand how coverage of other interventions 
delivered through ANC compares with that of two or 
more doses of IPTp-SP (IPTp-SP2+), the coverage of two 
or more doses of TT (TT2+) among primigravid women 
was compared to the coverage of IPTp-SP2+ among the 
same group of women. TT2+ coverage during pregnancy 
was calculated as the percentage of primigravid women 
in the two years prior to the survey who reported receiv-
ing at least two doses of TT.
The median, interquartile range (IQR), minimum 
and maximum across all survey estimates for the pre, 
#ANC visits in 2nd and 3rd trimesters - # IPTp doses given during these visits
#ANC visits in 2nd and 3rd trimesters
early-post, and late-post policy adoption periods are 
presented to provide insight into the central tendencies 
of the estimates of interest. Although it is informative to 
present statistics across groups of surveys, it is impor-
tant to stress that each of the surveys produces mean 
estimates that are only truly representative of the coun-
try and time period in which they are conducted, and the 
median value of the survey means cannot be interpreted, 




Data from 172,506 women across 44 surveys were used 
to assess ANC attendance. Overall, ANC attendance 
was high across surveys, with a median value of 92.7  % 
(IQR 87.4–95.6  %), 88.2  % (IQR 81.9–92.3  %), 76.1  % 
(IQR 67.5–81.6  %), and 48.6  % (IQR 41.7–59.6  %) of 
women attending at least one, two, three, and four visits, 
respectively. Only a small proportion of women (median 
of 7.2 %, IQR 3.6–19.7 %) attended ANC in the first tri-
mester. The first visit occurred at median gestational 
age of 4.6 months (IQR 3.9–4.9). There was an increase 
in prevalence of two or more ANC visits from a median 
of 83.5 % in the pre-policy period to 89.2 % in the early 
post-adoption phase, staying constant at 89.0  % in the 
late post- adoption period. The prevalence of three or 
more ANC visits varied little, from a median of 73.6 % in 
the pre-adoption period to 75.6 and 76.6  % in the early 
and late post-adoption periods, respectively.
Preventive treatment for malaria during pregnancy 
with sulfadoxine–pyrimethamine
Data from 205,200 women surveyed whose most recent 
birth was in the 2 years prior to the survey date were used 
to assess trends in IPTp-SP coverage over time. IPTp-SP 
became policy in 2004–2005 in 16 of the 31 countries in 
this analysis, and by the end of 2006 it was policy in 28 
countries (Additional file 1: Table S1). Ethiopia, Burundi 
and Swaziland never implemented IPTp-SP, and Rwanda 
implemented IPTp-SP only from 2005 to 2008 and then 
abandoned the policy. Prior to the existence of a policy 
in country, IPTp-SP2+ coverage was nearly 0 (median of 
1.1 % based on 15 pre-adoption surveys occurring 2003–
2012), as expected. Coverage of IPTp-SP2+ improved to 
a median of 20.2 % (IQR 12.9–40.3 %) in the 25 surveys 
conducted during 2003–2011 in the first 7 years follow-
ing adoption of IPTp-SP as policy, and to a median of 
29.6 % (IQR 20.1–42.5 %) in those 18 surveys conducted 
during 2004–2013 more than 7  years following policy 
adoption.
The coverage of three or more doses of IPTp-SP (IPTp-
SP3+) was a median of 0.5, 6.1, and 9.9  % for the pre-, 
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early-post, and late-post periods, respectively. For the 
late post-adoption period, the range was from 1.1 % (95 % 
CI 0.4–1.7 %) in Gabon in 2012 to 26.7 % (95 % CI 22.6–
30.7 %) in Liberia in 2011, although the highest observed 
coverage of IPTp-SP3+ was 43.1 % (95 % CI 40.2–46.0 %) 
in Zambia in 2007, in the early post-implementation 
period (this is the only available survey for Zambia). To 
better examine these trends, coverage among countries 
with two or more available surveys was assessed. This 
analysis shows some fluctuations in coverage over time, 
but an overall improvement (Fig. 2). The median 5 year 
average annualized difference in coverage of IPTp-SP2+ 
was 12.4 percentage points (IQR 3.8–28.0  %), and 5.5 
percentage points (IQR 0.8–8.4 %) for IPTp-SP3+.
Missed opportunities
Using data from 172,506 women for whom both IPTp-SP 
and ANC data were available, a median of 99.0  % (IQR 
96.5–99.2 %) of second and third trimester visits in pre-
implementation surveys, 79.0  % (IQR 71.0–91.4  %) in 
early post-implementation surveys and 72.9  % (IQR 
58.4–79.5  %) in late post-implementation surveys were 
missed opportunities for administration of IPTp-SP. The 
late post-implementation survey means ranged from 
48.8 % (95 % CI 47.8–49.8 %) in Malawi in 2010 to 97.8 % 
(95 % CI 97.0–98.6 %) in Gabon in 2012. Across all time 
points, Zambia had the fewest missed opportunities: 
44.3  % (95  % CI 42.6–46.1  %) in the early post-imple-
mentation period (no subsequent surveys were available 
for Zambia). Looking only at those countries where data 
from at least two time points were available shows that in 
individual countries there has been a reduction in missed 
opportunities over time, with a median 5  year average 
annualized difference of −13.0 percentage points (IQR 
−30.3 to −7.2 %) (Figs. 3, 4).
Coverage of IPTp‑SP2+ compared to TT2+
IPTp-SP2+ and TT2+ coverage was available from 44 
surveys, covering 45,808 women whose first pregnancy 
occurred in the 2  years preceding the survey. Median 
TT2+ coverage among primigravid women was 61.5  % 
(IQR 50.9–72.9  %), with a range from 31.6 % (95  % CIs 
27.1–36.0 %) in Niger (2006) to 85.0 % (95 % CIs 79.0–
91.0  %) in São Tomé and Príncipe (2008). Stratified by 
policy implementation period, the median TT2+ cover-
age in the pre-implementation surveys was 50.5 % (IQR 
41.7–72.1 %), 61.2 % (IQR 51.0–72.7 %) in the early post-
implementation surveys, and 68.0 % (IQR 60.0–73.8 %) in 
the late post-implementation surveys. Overall, coverage 
of TT2+ was markedly higher than IPTp-SP2+ cover-
age, with the exception of in Zambia, where coverage of 
IPTp-SP2+ exceeded that of TT2+, and Comoros, where 
IPTp-SP2+ and TT2+ coverage were approximately 
equal (Fig. 5). When this analysis was restricted to only 
women reporting attendance at two or more ANC visits, 
a similar pattern was seen (Additional file 2: Figure S1).
Discussion
Despite high levels of ANC attendance, and demon-
strated benefit of providing IPTp-SP, the coverage of 
IPTp-SP remains far below national and global targets 
(the President’s Malaria Initiative targets 85 % coverage, 
while Roll Back Malaria has called for 100 % coverage of 
at-risk populations), indicating that there are deficien-
cies in delivery of IPTp-SP at ANC. Although IPTp-SP 
coverage has generally increased over time, the change 
has been slow and much more progress is required to 
reach adequate coverage levels. This analysis clearly 
demonstrates that there are many missed opportunities 
to deliver IPTp-SP at ANC visits, far more so than for 
TT2+, highlighting the potential for improvements in 
service delivery at ANC to increase IPTp-SP coverage.
Although a recent meta-analysis finds that providers 
consistently state that women’s poor attendance at ANC 
is a significant contributing factor to the low coverage 
of IPTp-SP [14], the results from this study argue oth-
erwise. Across all surveys, 76  % of women attend ANC 
three times, and 88 % attend twice, with the first visit on 
average occurring in the fourth month, yet in those same 
surveys only 19 % received two doses of IPTp-SP. Even in 
the late post-adoption period, seven or more years after 
a country formally adopted an IPTp-SP policy, a median 
of 72.9 % of ANC visits represented missed opportunities 
for IPTp-SP delivery. The reasons for these missed oppor-
tunities cannot be determined by this study; however, 
other studies suggest that healthcare worker confusion 
about the dose and timing, as well as inadequate supplies 
(including SP stock-outs, and lack of cups and drinking 
water) all play a role [14]. In addition, in some coun-
tries, the existence of restrictive policies recommending 
administration of IPTp-SP during specific weeks of gesta-
tion, or prohibiting its administration in the last 4 weeks 
of pregnancy certainly contributed to at least some of 
these missed opportunities prior to 2013 [21].
As these data include women who gave birth as many 
as 2  years preceding the survey, it may be difficult to 
see an increase in IPTp-SP in surveys conducted within 
2  years of policy adoption. Therefore, coverage in both 
the early and late post-adoption periods was examined. 
Nonetheless, even when the data are restricted to only 
those surveys conducted seven or more years after policy 
adoption, coverage is still well below the universal cover-
age of preventive treatments recommended in the WHO 
Global Technical Strategy for Malaria 2016–2030 and 
called for in the Roll Back Malaria Action and Investment 
for Malaria 2016–2030 [22, 23]. Parasite resistance to SP 
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in sub-Saharan Africa is becoming an increasing concern 
[24], and SP is no longer recommended for treatment of 
acute malaria. Whether this leads healthcare workers to 
not administer IPTp-SP due to concerns that it will no 
longer be effective remains unclear. A study in Ghana 
found that healthcare workers understand the distinc-
tion between treatment and chemoprophylaxis [25], sug-
gesting that removing SP as a potential treatment should 
not have impacted administration of IPTp-SP as prophy-
laxis. However, research elsewhere found that women 
Fig. 2 Coverage of IPTp-SP2+ (a) and IPTp3+ (b) among pregnant women by survey year, in countries with two or more available surveys. IPTp2+: 
Receipt of two or more doses of IPTp, IPTp3+: Receipt of three or more doses of IPTp. Improvement in coverage of IPTp-SP2+ (a) and IPTp-SP3+ (b) 
over time by country, for countries with multiple available surveys. The coverage of 2+ doses of IPTp is markedly higher than the coverage of 3+ 
doses, but both general improved over time between 2003 and 2013. Reflecting this, the median 5-year average annualized difference in coverage 
of IPTp-SP2+ was 12.4 % (IQR 3.8–28.0 %) and 5.5 % (IQR 0.8–8.4 %) for IPTp-SP3+
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are prescribed SP for treatment, suggesting that not all 
healthcare workers appreciate this distinction [26], and 
still other research suggests that the recipients of the 
treatment also do not [27].
Zambia stands out as the only country with better cov-
erage of IPTp-SP2+ than of TT2+. While the majority 
of countries until recently promoted a two dose policy 
for IPTp-SP, Zambia has always promoted a three dose 
policy; this, in conjunction with the excellent collabora-
tion between the reproductive health department and 
the malaria control programme, has likely contributed 
to high two-dose coverage of IPTp [28]. Similarly, cover-
age of IPTp2+ is higher than average in Ghana where the 
policy is to provide three rather than two-doses of IPTp. 
In Ghana, a striking rise in coverage of IPTp2+, from 
44 % in 2008 to 65 % in 2011 [29] was seen after conduct-
ing a nationwide campaign promoting this policy. These 
data suggest that a three dose policy may be associated 
with higher coverage levels. Hopefully, as more countries 
move to recommending IPTp-SP at each ANC visit, cov-
erage of IPTp2+ will improve.
While the persistently low coverage of IPTp-SP is dis-
heartening, the consistently higher delivery of TT sug-
gests that IPTp-SP coverage can be improved. As TT is 
administered via injection and requires maintenance of 
the cold chain to preserve its effectiveness, it is seemingly 
a more complex intervention to deliver than IPTp-SP, 
thus it may at first seem surprising that delivery of TT2+ 
is consistently higher than that of IPTp-SP2+. How-
ever, IPTp is still relatively new compared to the more 
well-established TT. Although some countries adopted 
IPTp-SP as early as the 1990s, in most countries delivery 
of IPTp-SP was not a policy until 2004 [19]. In addition, 
IPTp-SP is recommended by malaria control programmes 
but implemented through reproductive healthcare; this 
may lead to less effective implementation. Unless there 
is excellent coordination between the malaria and repro-
ductive programmes, discrepancies will exist in the guid-
ance for IPTp-SP provided by the two programmes; this 
was highlighted in a recent review [21]. These discrep-
ancies may cause healthcare worker confusion, resulting 
in failure to properly implement IPTp-SP [13]. Another 
possible contributor to the higher coverage of TT2+ than 
IPTp-SP2+ is the fact that TT can be given in the first 
trimester, while IPTp-SP can only be given starting in the 
second trimester. However, given the relatively small pro-
portion of women who initiate ANC in the first trimes-
ter, this cannot fully explain the difference in coverage 
of the two interventions. Finally, differential recall bias 
may be contributing to the observed lower coverage of 
Fig. 3 Proportion of missed opportunities to deliver IPTp-SP over time, by survey year, for all countries with two or more available surveys. Missed 
opportunities for IPTp delivery over time by country, showing countries for which there were at least two surveys. Overall, there was a median aver-
age decrease of 13.3 percentage points (IQR 7.5–33.6 %) per 5-year period
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IPTp-SP compared to TT; women may be more likely to 
recall receiving an injection (a more painful experience) 
of TT than receiving pills for malaria prevention (which 
could even be mis-remembered as another intervention 
such as iron/folate supplementation), although this has 
not been studied. Further examination into the reasons 
for the discrepancy between delivery of IPTp-SP and TT 
and ways in which IPTp-SP treatment could benefit from 
the pre-existing structures of TT administration should 
be considered.
Limitations
This analysis has several limitations. In these surveys, 
information on ANC attendance and receipt of IPTp-SP 
was obtained for pregnancies over the 5 years preceding 
the survey based only on women’s recall. The potential 
effect of recall bias was minimized by limiting analy-
sis to the pregnancies of births in the 2 years preceding 
the survey. Also, although a large number of surveys are 
available across African countries during the time period 
covered by this analysis, for individual countries there 
may have been several years between surveys, making 
time trends difficult to assess. This was accounted for by 
examining changes across countries in five-year intervals 
since IPTp-SP policy adoption. Surveys were available for 
only a small number of countries in the last 2  years, so 
recent changes in IPTp-SP coverage could not be seen for 
many countries.
SP is contra-indicated in women who are HIV-positive 
and taking daily cotrimoxazole prophylaxis [24], but 
no data were available from these surveys to adjust for 
this. While in countries with high HIV prevalence, tak-
ing this into account may result in a significant decrease 
in missed opportunities, for most countries included in 
this analysis, the prevalence of HIV remains low and not 
accounting for women taking cotrimoxazole prophylaxis 
is unlikely to substantially affect the estimates of missed 
opportunities. Specifically, the median prevalence of 
HIV in 2008 (the median year of surveys included) in 
the countries in this analysis was 2.0 % [30], and the use 
of prophylactic cotrimoxazole was even lower. There-
fore, the effect on calculating missed opportunities for 
administration of IPTp-SP would appear to be minimal in 
most countries. This is not controlled for in the analysis, 
but future work could take into account the prevalence 
of HIV and use of cotrimoxazole and aim to adjust the 
expected level of IPTp-SP coverage given HIV levels.
The results of this analysis could be affected by how 
timing of ANC visits was addressed. In the surveys, only 
the timing of the first ANC visit was available. For preg-
nancies in which the first visit reportedly occurred in the 
first trimester, it was assumed that all subsequent visits 
occurred after the first trimester. If more than one visit 
occurred in the first trimester, this assumption could 
lead to an underestimate of opportunities to administer 
IPTp-SP and consequently an overestimate of missed 
opportunities. However, this appears to be unlikely as the 
vast majority of surveys (three-quarters) with available 
information showed that less than 20 % of women made 





























Pre-adopon Early post-adopon Late post-adopon
Fig. 4 Missed opportunities for IPTp-SP delivery by country and IPTp policy adoption period for countries with two or more surveys. Missed 
opportunities for IPTp delivery by country and adoption period, showing countries for which there were data points in both the early and late post 
adoption periods. Overall, missed opportunities were seen in a median of 78.5 % of visits (IQR 69.3–91.1 %) in the early post adoption period and 
71.6 % (IQR 56.8–78.9 %) in the late post adoption period
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mean gestational age at first ANC greater than 3 months. 
Similarly, it was assumed that all ANC visits occurred at 
least 1  month apart, as the timing of ANC visits, other 
than the first visit, were not available in the surveys. 
IPTp-SP doses should be administered at an interval of at 
least 1 month, meaning that subsequent ANC visits tak-
ing place less than 4 weeks apart should not be counted 
as missed opportunities (and doing so could lead to an 
overestimate). However, the magnitude of the impact 
of this limitation is likely small. Specifically, given that 
a median of less than 49 % of women attend more than 
three ANC visits and the median timing of first ANC 
visit is in the fourth month, it seems unlikely that a large 
fraction of those women who go on to receive two or 
three additional ANC visits would do so at intervals less 
than 4  weeks during the subsequent 6  months of their 
pregnancy.
In rare cases, women reported receiving more IPTp-
SP doses than ANC visits. This may be recall error, or it 
may reflect that the IPTp-SP questions in the survey are 
not sufficiently explicit to elicit accurate responses, that 
women are reporting treatment received for malaria as 
IPTp-SP, or that they are reporting the three IPTp-SP pills 
(one dose) as three separate doses. It could also reflect 
that they are receiving IPTp-SP from pharmacies or shops 
outside of their ANC visits. Not only would this contrib-
ute to error in the estimates of missed opportunities, but 
might be cause for larger public health concern if the 
quality of IPTp-SP outside of ANC is questionable.
Conclusions
Despite a decade of implementation, and demonstrated 
added benefit of IPTp even where women are sleep-
ing under ITNs [31], IPTp-SP coverage levels remain 
unacceptably low. Although many factors are involved 
[32], this analysis of missed opportunities clearly dem-
onstrates that a large proportion of women who attend 
ANC are not receiving IPTp-SP, and that if these missed 
opportunities for delivery were eliminated, coverage lev-
els would be much closer to the global targets, leading to 
improved maternal and newborn health [31]. The much 
higher levels of TT coverage suggest that it is possible 
for ANC clinics to improve service delivery. It is impor-
tant to further investigate the context-specific factors 
that are driving the differences in TT2+ coverage and 
IPTp-SP2+ coverage in order to better address the bot-
tlenecks to providing IPTp-SP, as well as to develop and 
assess interventions to address these gaps and challenges. 
The missed opportunities indicator could be added as a 
standard indicator to reports of future surveys, as this 
provides a useful assessment of the efficacy of IPTp-SP 
delivery at ANC.
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survey from each country. With the exception of Zambia, the delivery 
of TT2+ was notably better than that of IPTp2+ in all countries
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